3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
2
Other hematologic neoplasm
1
Gynecologic
1
Gastrointestinal
1
Dermatologic
1
Conditions
Carcinoma, Hepatocellular
81
Colorectal Neoplasms
39
Stomach Neoplasms
17
Carcinoma, Non-Small-Cell Lung
15
Liver Neoplasms
14
Neoplasms
11
Melanoma
11
Carcinoma, Renal Cell
11
Esophageal Neoplasms
10
Pancreatic Neoplasms
9
Carcinoma, Transitional Cell
8
Breast Neoplasms
8
Uterine Cervical Neoplasms
7
Triple Negative Breast Neoplasms
7
Squamous Cell Carcinoma of Head and Neck
7
Small Cell Lung Carcinoma
7
Ovarian Neoplasms
7
Head and Neck Neoplasms
7
Cholangiocarcinoma
7
Rectal Neoplasms
6
Neoplasm Metastasis
6
Colonic Neoplasms
6
Urinary Bladder Neoplasms
5
Gastrointestinal Neoplasms
5
Carcinoma, Merkel Cell
5
Biliary Tract Neoplasms
5
Prostatic Neoplasms
4
Sarcoma
3
Lung Neoplasms
3
Gallbladder Neoplasms
3
Interventions
trametinib
1
dabrafenib
1
atezolizumab
1
Valganciclovir
1
Tinzaparin
1
Polymerase Chain Reaction
1
Biopsy
1
4-phenylbutyric acid
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Lymphoproliferative Disorders
×
atezolizumab
×
Gastrointestinal
×
Clear all
NCT05770102
2025-11-24
DETERMINE
Cancer Research UK
Phase 2/3
Recruiting
30 enrolled